Current status of inflammasome blockers as anti-inflammatory drugs
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The inflammasomes have emerged as key mediators of inflammation and immunity, yet clinical application of this knowledge has been limited by a lack of specific and drug-like antagonists. Recent studies using inflammasome knockout mice have shown that different inflammasomes control immunity in different pathologies. Drug-like antagonists acting up- or down-stream of the inflammasome pathway have been successfully used in clinics as important therapeutics to treat different inflammatory diseases. AREAS COVERED: The current literature has been reviewed on the role of inflammasomes in inflammatory disease, focusing on potential therapeutic applications of selective inflammasome antagonists as anti-inflammatory agents. Particular emphasis has been placed on the potential role of the different inflammasomes in common inflammatory diseases. The latest clinical developments for drugs targeting inflammasome pathways are covered. EXPERT OPINION: Recent studies using inflammasome knockout mice suggest its importance as a potential therapeutic target for the treatment of inflammatory disease. However, efficacious antagonists for the inflammasome for use in clinical studies are still at an early stage of development. Developing selective inflammasome antagonists is a challenge that if met, offers promise for the treatment of chronic inflammatory diseases. Major developments in this area will include the identification of reliable high-throughput screening methods for compounds directly targeting inflammasome assembly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466 · cited 1×
“This is a potent cytokine that drives the host inflammatory response and has an essential role in innate as well as adaptive immunity [2,3].”
BackgroundHornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065 · cited 3×
“However, no difference has been found in inflammasome activation after exposure to silica crystals in animals deficient in the NAPDH oxidase subunit gp91 [31], while an impairment in IL-1b release after exposure to asbestos and silica crystals has been described in animals deficient in the NAPDH oxidase subunit p22 [3…”
BackgroundThioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 1×
“The inflammasome has also been identified as an important mediator in other pathologies, such as metabolic disorders [51] and cancer [52,53].”
BackgroundOxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis
Shimada, K., Crother, T. R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S., Ramanujan, V. K., Wolf, A. J., Vergnes, L., Ojcius, D. M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.009 · Cited by 2,282 · cited 1×
“These ROS are derived from the mitochondria and can generate oxidized mitochondrial DNA that is released into the cytosol directly activating the NLRP3 inflammasome [33,34].”
BackgroundGhiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 1×
“This is a potent cytokine that drives the host inflammatory response and has an essential role in innate as well as adaptive immunity [2,3].”
BackgroundThe Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101405 · Cited by 1,618
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445 · cited 1×
“Studies on the NLRP3 inflammasome have shown that lowering potassium is a requirement for its activation in response to ATP and nigericin [11,12,22], but more importantly it seems to be a common feature of all NLRP3 activator signals [23].”
BackgroundCaspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria
Miao, E. A., Leaf, I. A., Treuting, P. M., Mao, D. P., Dors, M., Sarkar, A., Warren, S. E., Wewers, M. D., & Aderem, A. (2010) · Nature Immunology · doi:10.1038/ni.1960 · Cited by 1,336
Cited by
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Deubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity
Py, B. F., Kim, M.-S., Vakifahmetoglu-Norberg, H., & Yuan, J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.11.009 · Cited by 715
NLRP3 Inflammasome Mediates Chronic Mild Stress-Induced Depression in Mice via Neuroinflammation
Zhang, Y., Liu, L., Liu, Y.-Z., Shen, X.-L., Wu, T.-Y., Zhang, T., Wang, W., Wang, Y.-X., & Jiang, C.-L. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv006 · Cited by 325
He, Y., Varadarajan, S., Muñoz-Planillo, R., Burberry, A., Nakamura, Y., & Núñez, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.515080 · Cited by 268
Marchetti, C., Chojnacki, J., Toldo, S., Mezzaroma, E., Tranchida, N., Rose, S. W., Federici, M., Van Tassell, B. W., Zhang, S., & Abbate, A. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000053 · Cited by 264
Metadata
- Authors
- López-Castejón, G., & Pelegrín, P.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2012-05-22
- Volume
- 21
- Issue
- 7
- Pages
- 995-1007
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2071844617
- Cited by
- 75
- References
- 20
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current status of inflammasome blockers as anti-inflammatory drugs. https://app.cochat.ai/papers/10.1517/13543784.2012.690032
- The paper
- López-Castejón, G., & Pelegrín, P. (2012). Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.2012.690032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.